Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 17, 2019

Aivita Biomedical secures US FDA approval for melanoma drug trial

Aivita Biomedical has secured approval from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to start a Phase Ib clinical trial to assess AV-MEL-1 for the treatment of patients with metastatic melanoma.

Aivita Biomedical has secured approval from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to start a Phase Ib clinical trial to assess AV-MEL-1 for the treatment of patients with metastatic melanoma.

AV-MEL-1 is developed by Aivita as part of its ‘Root of Cancer’ immunotherapy technology programme.

The company is expected to study the ‘Root of Cancer’ technology in combination with anti-PD-1 checkpoint inhibitors.

The open-label, single-arm trial aims to determine the safety of the AV-MEL-1 and anti-PD1 monoclonal antibodies combination.

It also intends to evaluate the efficacy of the treatment in around 14 to 20 patients with measurable metastatic melanoma.

“This combination therapy is a natural extension of our technology, and indeed, checkpoint inhibitors.”

Primary safety objective of the trial is the number of grade three to five adverse events with AV-MEL-1 plus PD-1 against PD-1 alone.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Aivita chief medical officer Dr Robert Dillman said: “As our non-responding patients all have elevated checkpoint levels, this combination therapy is a natural extension of our technology, and indeed, checkpoint inhibitors.

“Now that the limitations of anti-PD-1 therapy have been realised, many experts are touting the advantages of adding a personalised vaccine to an anti-PD-1 approach.”

Aivita previously tested its personalised patient-specific platform cancer technology in two Phase II studies that included patients with advanced melanoma.

The technology is designed to selectively target the patient’s tumour-initiating cells. It was also approved for use in a Phase III trial.

These clinical studies showed the efficacy of the technology in a randomised trial, which resulted in a 72% two-year survival rate and a 54% five-year survival rate among the patients.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU